To include your compound in the COVID-19 Resource Center, submit it here.

AZ reports detailed lung cancer data for Imfinzi, Tagrisso

After stumbling on a disappointing readout from the Phase III MYSTIC trial, AstraZeneca plc (LSE:AZN; NYSE:AZN) regained some footing in the lung cancer space over the weekend with presentations at the European Society for Medical Oncology meeting in Madrid. The pharma reported detailed data from two Phase III trials evaluating Imfinzi durvalumab and Tagrisso osimertinib

Read the full 557 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers